Maria Berkman, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement.
Prior to joining Broadview Ventures Maria was a management consultant at Monitor Group (now Monitor Deloitte), where she specialized in life sciences with a focus corporate strategy, franchise and asset-level commercialization strategy, and competitive strategic planning for a broad range of biopharma clients. Before joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital, with a focus on General Surgery. Maria earned her MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery. Maria earned her MBA from the Anderson School of Management at UCLA.
Maria currently serves as the Board Observer for 480 Biomedical, Apama, BioKier, Cardero, Cardialen, Vascular Graft Solutions and Zumbro Discovery and is a Board Director of FineHeart.
In addition to her role at Broadview Ventures, Maria contributes time as a grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD Biomed Accelerator in Tel Aviv, Israel.
Maria is attending / has attended:
The 2017 New England Venture Summit
The 2016 New York Venture Summit
The 2015 New England Venture Summit
The Life Sciences and Healthcare Venture Summit 2014